Home
Article in Science Daily on the report on the survival rates in mouse models of mesothelioma, published in Cancer Immunology Research, by a team from the Vaccine and Immunotherapy Center at Massachusetts General Hospital.

Article in Science Daily on the report on the survival rates in mouse models of mesothelioma, published in Cancer Immunology Research, by a team from the Vaccine and Immunotherapy Center at Massachusetts General Hospital.

ScienceDaily

Combination immunotherapy improves survival in mouse models of mesothelioma

Mass. The general team reports promising preclinical results against uniformly fatal tumor

Date:

April 2, 2018

Source:

Massachusetts General Hospital

Summary:

Investigators have found that combined treatment with two cancer immunotherapy drugs — one a novel immune modulator and one that focuses and activates the anti-tumor immune response — significantly prolonged survival in mouse models of the aggressive cancer malignant mesothelioma.

https://www.sciencedaily.com/releases/2018/04/180402142458.htm

Leave a Comment